Abbott price target lowered to $141 from $142 at Raymond James

Raymond James lowered the firm’s price target on Abbott (ABT) to $141 from $142 and keeps an Outperform rating on the shares. Abbott’s Q2 results were strong in Med Devices, but idiosyncratic issues are weighing on Diagnostics growth, which is slowing Abbott’s momentum, the analyst tells investors in a research note. The firm views these issues as transient.